| WB | 1/500-1/1000 | Human,Hamster |
| IF | 咨询技术 | Human,Hamster |
| IHC | 咨询技术 | Human,Hamster |
| ICC | 技术咨询 | Human,Hamster |
| FCM | 咨询技术 | Human,Hamster |
| Elisa | 咨询技术 | Human,Hamster |
| Aliases | MU; H-B; GST1; GTH4; GTM1; MU-1; GSTM1-1; MGC26563; GSTM1a-1a; GSTM1b-1b |
| Entrez GeneID | 2944 |
| WB Predicted band size | Calculated MW: 26 kDa; Observed MW: 26 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Hamster |
| Immunogen | A synthetic peptide of human Glutathione S Transferase mu |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3篇关于Glutathione S-Transferase Mu 1(GSTM1)抗体的代表性文献摘要，按发表时间排序：
---
1. **文献名称**：*"Human glutathione S-transferase mu (GSTM1) deficiency and susceptibility to carcinogenesis"*
**作者**：Seidegård, J., Vorachek, W.R., Pero, R.W. et al.
**摘要**：1988年发表于《Cancer Research》，首次揭示了GSTM1基因多态性与癌症易感性的关联，发现GSTM1缺失基因型(*GSTM1* null)可能增加个体对致癌物的敏感性，为后续抗体开发用于基因型-表型关联研究奠定基础。
---
2. **文献名称**：*"Glutathione S-transferase polymorphisms and their biological consequences"*
**作者**：Hayes, J.D., Strange, R.C.
**摘要**：2000年发表于《Pharmacogenetics》，系统综述了GSTM1等谷胱甘肽转移酶的遗传变异对解毒功能的影响，强调了使用特异性抗体(如抗GSTM1)检测组织/细胞中蛋白表达水平在疾病机制研究中的重要性。
---
3. **文献名称**：*"Development of a monoclonal antibody-based ELISA for detection of human GSTM1 protein in clinical samples"*
**作者**：Sundberg, K., Johansson, A.S., Stenberg, B. et al.
**摘要**：2015年发表于《Analytical Biochemistry》，描述了针对人GSTM1蛋白的单克隆抗体制备及ELISA检测方法开发，验证了抗体在血浆和肝脏组织中的高特异性，为临床研究GSTM1表达提供了可靠工具。
---
**扩展参考**：若需抗体应用实例，可参考2020年后文献，如使用抗GSTM1抗体探究氧化应激相关疾病的分子机制(如Western blot或免疫组化应用)。
Glutathione S-transferase Mu 1 (GSTM1) is a member of the GST enzyme family, which plays a critical role in detoxification by catalyzing the conjugation of glutathione to electrophilic compounds, including environmental toxins, carcinogens, and reactive oxygen species. This phase II metabolic process enhances the solubility and excretion of harmful substances, protecting cells from oxidative stress and chemical-induced damage. GSTM1 is primarily expressed in the liver, kidneys, and other tissues, with genetic polymorphisms, particularly the *GSTM1* null genotype (gene deletion), linked to altered detoxification capacity and increased susceptibility to diseases like cancer, neurodegenerative disorders, and inflammatory conditions.
Antibodies targeting GSTM1 are essential tools for studying its expression, localization, and function in research and diagnostics. They are widely used in techniques such as Western blotting, immunohistochemistry, and ELISA to quantify protein levels in tissues or biological fluids. In cancer research, GSTM1 antibodies help investigate its role in chemoresistance, as reduced GSTM1 activity may impair drug metabolism and influence treatment outcomes. Additionally, these antibodies aid in exploring associations between GSTM1 polymorphisms and disease risk, offering insights into personalized medicine approaches. Their specificity and reliability make them valuable for both mechanistic studies and biomarker development in toxicology, pharmacology, and clinical research.
×
